The clause 5.4.7 in ISO SNI 15189: 2012 requires medical laboratories to have a procedure for the time limit of sample storage, including for therapeutic drug monitoring (TDM) services in the clinical setting. In TDM, saliva is used as a biological matrix due to the non-invasive and convenient collection technique especially for the children and geriatric patients. Phenytoin (PHT) concentration in saliva is known to significantly correlate with its free serum concentration in respect of the clinical response. This research aimed to perform a stability test of PHT in spiked-saliva by utilizing HPLC-UV for the service protocol to monitor PHT concentration in TDM services. PHT concentration was determined using Reversed-Phase HPLC at 200 nm wavelength with C8 (4.6 x 150 mm; 5 µm) stationary phase and methanol: water (55:45) mobile phase. The stability test was conducted on PHT in spiked-saliva at 1.5 and 4 µg/mL concentrations stored at a room temperature and -20°C for one month. The results showed that PHT stock solution in methanol solvent was stable for up to 30 days at 4°C. However, the saliva samples containing PHT were stable only for less than 6 hours at a room temperature or when stored for less than 7 days at -20°C. In contrast, the analyte of extracted PHT in spiked-saliva remained stable for a maximum of 24 hours of storage at room temperature. We recommend that samples of patients’ saliva which are extracted and stored at 4°C remain usable for an adjustment of dose and PHT toxicity diagnosis in clinical settings.

1.
B.F
Kirmani
,
D.M.
Robinson
,
A.
Kikam
,
E.
Fonkem
and
D.
Cruz
,
Curr Treat Options Neurol
16
,
295
(
2014
).
2.
C. Y.
Hsu
,
C. Y.
Cheng
,
J. D.
Lee
,
M.
Lee
and
B.
Ovbiagele
,
BMC Neurol
21
,
26
(
2021
).
3.
World Health Organization
, Guidelines on Neonatal Seizures (
WHO Press
,
Geneva Switzerland
,
2011
) pp
7
9
.
4.
C.
Minardi
,
R.
Minacapelli
,
P.
Valastro
,
F.
Vasile
,
S.
Pitino
,
P.
Pavone
,
M.
Astuto
and
P.
Murabito
,
J Clin Med
8
,
39
(
2019
).
5.
M.D.
Lyttle
,
N. E. A.
Rainford
,
C.
Gamble
,
S.
Messahel
,
A. Humphreys. H.
Hickey
,
K.
Woolfall
,
L.
Roper
,
J.
Noblet
,
E. D.
Lee
,
S.
Potter
,
P.
Tate
,
A.
Iyer
,
V.
Evans
and
R. E.
Appleton
,
The Lancet
393
,
2125
2134
(
2019
).
6.
S.
Alqahtani
,
T.
Alzaidi
,
M.
Alotaibi
and
A.
Alsultan
,
PHA
104
,
60
66
(
2019
).
7.
J.R.
Hughes
,
Epilepsy Behav
14
,
280
287
(
2009
).
8.
L.
Hutchinson
,
M.
Sinclair
,
B.
Reid
,
K
,
Burnett
and
B.
Callan
,
Br. J. Clin. Pharmacol.
84
,
1089
1108
(
2018
).
9.
N.
Idkaidek
and
T.
Arafat
,
Mol. Pharmaceutics
9
,
2358
2363
(
2012
).
10.
C.
Hiemke
,
N.
Bergemann
,
H. W.
Clement
,
A.
Conca
,
J.
Deckert
,
K.
Domschke
,
G.
Eckermann
,
K.
Egberts
,
M.
Gerlach
,
C.
Greiner
,
G.
Gründer
,
E.
Haen
,
U.
Havemann-Reinecke
,
G.
Hefner
,
R.
Helmer
,
G.
Janssen
,
E.
Jaquenoud
,
G.
Laux
,
T.
Messer
,
R.
Mössner
,
M. J.
Müller
,
M.
Paulzen
,
B.
Pfuhlmann
,
P.
Riederer
,
A.
Saria
,
B.
Schoppek
,
G.
Schoretsanitis
,
M.
Schwarz
,
M. Silva
Gracia
,
B.
Stegmann
,
W.
Steimer
,
J. C.
Stingl
,
M.
Uhr
,
S.
Ulrich
,
S.
Unterecker
,
R.
Waschgler
,
G.
Zernig
,
G.
Zurek
and
P.
Baumann
,
Pharmacopsychiatry
51
,
9
62
(
2018
).
11.
R.
Dwivedi
,
M.
Singh
,
T.
Kaleekal
,
Y. K.
Gupta
and
M.
Tripathi
,
Int J Neurosci
126
,
972
978
(
2016
).
12.
M. E.
Ruiz
,
P.
Fagiolino
,
P. M.
de Buschiazzo
and
M. G.
Volonté
,
Eur J Drug Metab Pharmacokinet
36
,
229
236
(
2011
).
13.
J.
Carvalho
,
T.
Rosado
,
M.
Barroso
and
E.
Gallardo
,
J Anal Toxicol
43
,
61
71
(
2019
).
14.
R.
Hösli
,
A.
Tobler
,
S.
König
and
S.
Mühlebach
,
J. Anal. Toxicol.
37
,
102
109
(
2013
).
15.
T.
Tuzimski
and
A.
Petruczynik
,
Molecules
25
,
4026
(
2020
).
16.
P. N.
Patsalos
and
D. J.
Berry
,
Ther Drug Monit
35
,
4
29
(
2013
).
17.
P. D. V.
de Almeida
,
A. M. T.
Grégio
,
M. A. N.
Machado
,
A. A. S.
de Lima
and
L. R.
Azevedo
,
J Contemp Dent Pract
9
,
72
80
(
2008
).
18.
Center for Drug Evaluation and Research
, Reviewer Guidance: Validation of Chromatographic Methods (
US Food and Drug Administration
,
1994
), pp.
21
26
.
19.
R. J.
Baumann
,
Journal of Pharmacy Practice
20
,
147
157
(
2007
).
20.
Center for Drug Evaluation and Research (CDER)
, Bioanalytical method validation Guidance for Industry (
U.S. Department of Health and Human Services Food and Drug Administration
,
2018
), pp.
5
11
.
21.
European Medicines Agency
, Guideline on Bioanalytical Method Validation (
Committee for Medicinal Products for Human Use (CHMP
),
2011
), pp.
4
9
.
22.
M. W.
Dong
, Handbook of Pharmaceutical Analisys by HPLC (
Elsevier Academic Press
,
USA
,
2005
), pp
22
30
.
23.
G. M.
Heam
, A guide to Validation in HPLC (
Norwalk, USA
:
Perkin-Elmer Corp
,
1992
).
24.
N.
Dyson
, Chromatographic Integration Methods (
The Royal Society of Chemistry
,
Cornwall, UK
,
1998
), pp.
27
28
.
25.
F.
Rouessac
and
A.
Rouessac
, Chemical Analysis: Modern Instrumentation Methods and Techniques (
Wiley
,
2007
), pp.
9
18
.
26.
L. A. S.
Nunes
,
S.
Mussavira
and
O. S.
Bindhu
,
Biochem Med (Zagreb)
25
,
177
192
(
2015
).
27.
N. V.
de Merbel
,
N.
Savoie
,
M.
Yadav
,
Y.
Ohtsu
,
J.
White
,
M. F.
Riccio
,
K.
Dong
,
R.
de Vries
and
J
,
Diancin
,
AAPS J.
16
,
392
399
(
2014
).
28.
Bove’
R.
Temperature measurement in the clinical laboratory…good enough isn’t good enough. MLO
2011
. https://www.mlo-online.com/temperature-measurement-in-the-clinical-laboratorygood-enough-isnt-good-enough.php (accessed February 27, 2018).
29.
M.
Tennison
,
I.
Ali
,
M. V.
Miles
,
O.
D’Cruz
,
B.
Vaughn
and
R.
Greenwood
,
Ther Drug Monit
26
,
295
299
(
2004
).
30.
A. B.
Justino
,
R. R.
Teixeira
,
L. G.
Peixoto
,
O. L. B.
Jaramillo
and
F. S.
Espindola
,
Scand. J. Clin. Lab.
77
,
415
422
(
2017
).
This content is only available via PDF.
You do not currently have access to this content.